Implanet SA (FR:ALIMP)
:ALIMP
Want to see FR:ALIMP full AI Analyst Report?
ALIMP Stock Chart & Stats
€0.26
<€0.01(1.57%)
At close: 4:00 PM EST
€0.26
<€0.01(1.57%)
Day’s Range― - ―
52-Week Range€0.08 - €0.44
Previous CloseN/A
Volume2.90K
Average Volume (3M)332.66K
Market Cap
€26.61M
Enterprise Value€29.49M
Total Cash (Recent Filing)€3.01M
Total Debt (Recent Filing)€5.92M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Sep 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding143,818,970
10 Day Avg. Volume485,065
30 Day Avg. Volume332,657
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)70.59
Price to Sales (P/S)2.29
P/FCF Ratio-13.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth from 2023–2025 indicates accelerating clinical adoption and market penetration of Implanet's implant systems. A rising revenue base strengthens scale effects, improves fixed-cost absorption, and provides a clearer runway to convert higher sales into operating leverage and slower cash burn.
Improving Gross MarginsA material gross margin increase suggests better pricing, favorable product mix, or manufacturing efficiencies. Sustained higher gross margins enhance the company's ability to cover R&D and SG&A, shorten time to profitability, and structurally improve free cash flow potential as revenue scales.
Recurring Procedural Demand / Business ModelImplants and compatible instruments drive repeatable, procedure-linked demand and platform stickiness with hospitals and surgeons. This structural revenue pattern supports predictability, long-term customer relationships, and higher lifetime value per installed system versus one-off device sales.
Bears Say
Persistent LossesOngoing negative profitability (2025 net margin ~-35%) means internal earnings cannot fund growth or rebuild equity. Persistent losses increase financing needs, reduce reinvestment capacity, and raise the bar for management to demonstrate a durable path to sustained operating profits.
Elevated Leverage And Thin EquityA highly leveraged balance sheet with minimal equity cushion constrains financial flexibility and amplifies insolvency risk if performance slows. Such capital structure limits the company's ability to absorb shocks, pursue opportunities, or obtain favorable financing without dilution or costly terms.
Negative Operating Cash Flow / Funding RelianceConsistent negative operating and free cash flow forces reliance on external funding to support operations and commercialization. Dependence on new capital creates execution risk, potential dilution, and can limit investment in sales, clinical work, or product development if funding conditions tighten.
ALIMP FAQ
What was Implanet SA’s price range in the past 12 months?
Implanet SA lowest stock price was €0.08 and its highest was €0.44 in the past 12 months.
What is Implanet SA’s market cap?
Implanet SA’s market cap is €26.61M.
When is Implanet SA’s upcoming earnings report date?
Implanet SA’s upcoming earnings report date is Sep 15, 2026 which is in 85 days.
How were Implanet SA’s earnings last quarter?
Implanet SA released its earnings results on Feb 24, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.017.
Is Implanet SA overvalued?
According to Wall Street analysts Implanet SA’s price is currently Overvalued.
Does Implanet SA pay dividends?
Implanet SA does not currently pay dividends.
What is Implanet SA’s EPS estimate?
Implanet SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Implanet SA have?
Implanet SA has 143,818,970 shares outstanding.
What happened to Implanet SA’s price movement after its last earnings report?
Implanet SA reported an EPS of -€0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 16.162%.
Which hedge fund is a major shareholder of Implanet SA?
Currently, no hedge funds are holding shares in FR:ALIMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Implanet SA
Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. Its spinal offerings encompass various posterior fixation systems, including the Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw lines. Furthermore, Implanet S.A. provides knee prostheses, which are marketed under the Madison brand. The company has a significant strategic alliance with Shanghai Sanyou Medical Co, Ltd. Established in 2006, Implanet S.A. operates from its headquarters in Martillac, France.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Theraclion SA
―
Diagnostic Medical Systems
―
Median Technologies
―
Affluent Medical SA
―